The product described as Ruthenium Catalyst Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is controlled as a pharmaceutical-grade ruthenium coordination complex intended for development of solid oral dosage forms and sterile injectable presentations. The term “catalyst” in the product designation reflects the well-characterised coordination behaviour of the ruthenium centre; once the substance is specified as an API, it is released under active pharmaceutical ingredient controls rather than industrial catalyst specifications. Model designations are supplier-specific and do not follow a harmonised USP, Ph. Eur., or JP monograph. Regulatory dossiers identify the substance by chemical name, molecular formula, and manufacturer product code rather than by a universal model number. The material is supplied for formulation screening, clinical manufacturing, and commercial scale-up, with route-specific attention to particle size, residual solvents, elemental impurities, polymorphic identity, and microbial quality. Because no public compendial monograph exists for this specific ruthenium API configuration, specification limits are established through the chemistry, manufacturing, and controls dossier and are justified against ICH Q7, ICH Q3D, and the relevant pharmacopoeial general chapters.

What release specifications apply to the oral and injectable routes?

Release of the API for oral solid and injectable formulation is governed by a control matrix that combines identity confirmation, assay, purity, residual solvents, water content, elemental impurities, and microbial attributes. Identity is confirmed by X-ray powder diffraction against a qualified reference pattern under USP <941> and by infrared absorption or attenuated total reflectance spectroscopy under USP <197>. Assay may be performed by validated high-performance liquid chromatography with ultraviolet or visible detection for the intact ruthenium complex, with orthogonal metal content determination by inductively coupled plasma mass spectrometry or optical emission spectrometry after acid digestion. Residual solvents are controlled under USP <467> against ICH Q3C limits. Water content is determined by Karl Fischer titration under USP <921>. Elemental impurities are measured by USP <233> and assessed against ICH Q3D permitted daily exposure values, with ruthenium assigned to the Class 2B category. For oral dosage forms, microbial examination follows USP <61> and USP <62>. For injectable presentations, sterility testing under USP <71> and bacterial endotoxin testing under USP <85> are mandatory. The following method matrix summarises the route-specific release framework; acceptance limits are derived from stability and toxicological data because published data for this specific configuration is limited.

Because the model number is supplier-defined, the certificate of analysis typically carries a manufacturer-specific product code that encodes the ruthenium oxidation state, counterion, and manufacturing route. The product is not identified by a harmonised pharmacopoeial model number, and equivalence between suppliers should not be assumed from trade designations alone. Technical dossiers should contain a complete active substance master file or drug master file reference, the manufacturing process description, process-related impurity profiles, and stability data generated under ICH Q1A conditions. For an injectable grade, additional documentation should demonstrate control of particulate matter, filter compatibility, and container closure integrity. Published data for this specific product is limited; consequently, compendial substitution is not automatic and should be supported by comparative release data and stability bridging studies.

Solid oral processing windows and excipient compatibility constraints

For tablet and capsule development, direct compression is typically evaluated first because it avoids exposing the ruthenium coordination sphere to granulation fluids. If the API has poor flow or low bulk density, dry granulation by roller compaction is generally preferred over aqueous wet granulation unless forced degradation data demonstrate acceptable ligand-exchange stability at processing temperature and time. Particle sizing by laser diffraction under USP <429> is used to characterise the granulation feed, and the acceptance range is tied to dissolution performance rather than assigned as a universal value. In production-scale tablet lines, the API is blended with excipients such as microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate; however, excipients with reducing end groups or high chloride content may alter the ligand sphere of the ruthenium centre. Aqueous wet granulation in a high-shear granulator is not assumed compatible solely from the chemical structure. The granulation process should be challenged with forced degradation samples at 25 °C ± 2 °C and 40 °C ± 2 °C, and granulating fluid contact should be limited to the shortest workable time. Tablet compression should be monitored for sticking, picking, and tooling accumulation because metal coordination compounds can alter charge density and adhesion. Tooling with chromium nitride or diamond-like carbon coatings is sometimes used to reduce picking at higher turret speeds. Immediate-release dissolution testing according to USP <711> in media at pH 1.2, pH 4.5, and pH 6.8 is used to detect formulation-dependent release changes, particularly when the API is processed by wet granulation.

For dry granulation and capsule filling, control of storage humidity is critical. Long-term stability per ICH Q1A uses 25 °C ± 2 °C and 60% RH ± 5%, while accelerated testing uses 40 °C ± 2 °C and 75% RH ± 5%. If the API shows hygroscopicity above 60% RH, pre-drying and moisture-controlled dispensing are required before blending. Roller compaction should be operated at parameters that avoid excessive pressure-induced phase transformation of the API; if the material contains a defined polymorph, XRPD under USP <941> should be repeated after compaction to confirm form retention. Capsule formulations should be filled under low-humidity conditions, and the finished capsule shell should be specified for moisture vapour transmission rate where appropriate. Published data for this specific ruthenium API configuration is limited, so processing windows must be established by design of experiments rather than imported from other metal-coordination APIs.

When injectable formulation moves from aseptic filtration to terminal sterilisation

Injectable presentations are prepared by dissolving the ruthenium API in chloride-containing or chloride-free aqueous media depending on the stability of the coordination complex. The solution is filtered through a 0.22 µm PVDF or polyethersulfone membrane in an ISO 7 aseptic processing area, with critical operations exposed to ISO 5 air quality. Terminal sterilisation at 121 °C for 15 min is not assumed suitable for this product category. Ruthenium complexes may undergo thermal aquation, ligand substitution, or reduction of the metal centre during autoclaving, and the maximum sterilisation hold time and F0 should be justified with forced degradation data generated under the proposed sterilisation cycle. If terminal sterilisation is required, the effect on assay, related substances, pH, colour, and particulate matter should be quantified before release. Aseptic filtration is frequently the preferred sterilising method when aqueous stability is insufficient. Vial filling on a peristaltic or rotary piston line is performed under low-actinic light to reduce photodegradation. For formulations with unacceptable solution stability, lyophilisation may be used. The lyophilisation cycle should be designed to keep the product below its collapse temperature, which is typically determined by freeze-drying microscopy. Container closure integrity is tested by dye ingress, vacuum decay, or helium leak methods under USP <1207> guidance, and the choice of stopper and vial should be justified by extractables and leachables data. Published data for this specific ruthenium API configuration is limited, so terminal sterilisation cannot be assumed from platinum API precedents.

Compared with platinum APIs such as cisplatin and carboplatin, ruthenium coordination complexes may adopt octahedral geometry and exhibit slower ligand-exchange kinetics. This can reduce off-target aquation in formulation but demands tighter control of chloride concentration, pH, and light exposure. Palladium residues in pharmaceutical synthesis are controlled as impurity elements rather than as active substances; oxidising conditions may generate palladium species that are removed by scavenging, crystallisation, or chromatography. The ruthenium pharma-grade API, by contrast, is the active substance and is specified for identity, assay, purity, and stability. The following comparative matrix summarises key formulation-relevant differences between ruthenium APIs, platinum APIs, and palladium catalyst residues.

Manufacture of the ruthenium API should follow ICH Q7 for active pharmaceutical ingredients, and finished dosage form production should comply with 21 CFR 210 and 21 CFR 211. Supply-chain documentation includes the active substance master file, certificate of analysis, stability protocol under ICH Q1A, and route-specific elemental impurity risk assessment under ICH Q3D. The certificate of analysis reports assay by validated HPLC or ICP-MS, residual solvents by USP <467>, and elemental impurities by USP <233> against ICH Q3D limits. For injectable use, the dossier should also document sterilising filter validation, container closure integrity, bacterial endotoxin control, and compatibility with the intended administration fluid. Because the product is not assigned a harmonised pharmacopoeial model number, batch-to-batch equivalence is maintained through the supplier’s validated process and the analytical release matrix rather than through trade-name substitution.